Literature DB >> 15824514

A2A adenosine receptor agonist and PDE4 inhibition delays inflammation but fails to reduce injury in experimental obstructive nephropathy.

Bärbel Lange-Sperandio1, Michael S Forbes, Barbara Thornhill, Mark D Okusa, Joel Linden, Robert L Chevalier.   

Abstract

BACKGROUND: Renal interstitial inflammation is a consequence of unilateral ureteral obstruction (UUO). Following ischemia/reperfusion, adenosine reduces renal inflammation and injury, effects which are potentiated by type 4 phosphodiesterase inhibitors. We therefore studied the effects of A2A adenosine receptor agonist (ATL146e), and PDE4 inhibitor (rolipram) in mice subjected to UUO.
METHODS: Mice were subjected to UUO or sham operation, and received either vehicle or ATL146e + rolipram by osmotic minipump for 1 or 7 days. At 1, 3, 7, or 14 days after operation, renal macrophage infiltration, apoptosis, proliferation, tubular atrophy, and interstitial fibrosis were quantitated, and expressions of IL-6 and TGF-beta mRNA were determined.
RESULTS: ATL146e + rolipram reduced macrophage infiltration by 40% after 3 days UUO (p < 0.05). Tubular apoptosis, tubular atrophy, and interstitial fibrosis were increased by 7 or 14 days UUO, but were unaffected by ATL146e + rolipram. However, cellular proliferation was increased by ATL146e + rolipram in the obstructed kidney. ATL146e + rolipram had no effect on the renal expression of IL-6 and TGF-beta mRNA.
CONCLUSIONS: A2A receptor activation and PDE4 inhibition transiently reduce renal macrophage infiltration, but do not ameliorate the renal response to UUO. We speculate that the persistent stimulus for inflammation triggered by UUO cannot be reversed by agents that suppress inflammatory cell activation alone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15824514     DOI: 10.1159/000085057

Source DB:  PubMed          Journal:  Nephron Exp Nephrol        ISSN: 1660-2129


  8 in total

1.  The immunosuppressive role of adenosine A2A receptors in ischemia reperfusion injury and islet transplantation.

Authors:  Preeti Chhabra; Joel Linden; Peter Lobo; Mark Douglas Okusa; Kenneth Lewis Brayman
Journal:  Curr Diabetes Rev       Date:  2012-11

2.  Role of inflammation in túbulo-interstitial damage associated to obstructive nephropathy.

Authors:  María T Grande; Fernando Pérez-Barriocanal; José M López-Novoa
Journal:  J Inflamm (Lond)       Date:  2010-04-22       Impact factor: 4.981

3.  Major histocompatibility class II transactivator expression in smooth muscle cells from A2b adenosine receptor knock-out mice: cross-talk between the adenosine and interferon-gamma signaling.

Authors:  Yong Xu; Katya Ravid; Barbara D Smith
Journal:  J Biol Chem       Date:  2008-03-21       Impact factor: 5.157

4.  Implications of oxidative stress in the pathophysiology of obstructive uropathy.

Authors:  Martin Zecher; Cristián Guichard; María José Velásquez; Gabriel Figueroa; Ramón Rodrigo
Journal:  Urol Res       Date:  2008-12-12

5.  Activation of AMPK inhibits inflammation in MRL/lpr mouse mesangial cells.

Authors:  A Peairs; A Radjavi; S Davis; L Li; A Ahmed; S Giri; C M Reilly
Journal:  Clin Exp Immunol       Date:  2009-06       Impact factor: 4.330

6.  Effect of adenosine in extracellular matrix synthesis in human and rat mesangial cells.

Authors:  Carlos Martínez-Salgado; Begoña García-Cenador; Isabel Fuentes-Calvo; Juan F Macías Núñez; José M López-Novoa
Journal:  Mol Cell Biochem       Date:  2007-07-17       Impact factor: 3.396

7.  Inhibition of 12/15-Lipoxygenase Reduces Renal Inflammation and Injury in Streptozotocin-Induced Diabetic Mice.

Authors:  Jessica Faulkner; Chelsey Pye; Mohamed Al-Shabrawey; Ahmed A Elmarakby
Journal:  J Diabetes Metab       Date:  2015-05-30

8.  Tubulointerstitial macrophage accumulation is regulated by sequentially expressed osteopontin and macrophage colony-stimulating factor: implication for the role of atorvastatin.

Authors:  Shaojiang Tian; Guohua Ding; Ruhan Jia; Guili Chu
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.